Matrix metalloproteinases as therapeutic targets in arthritic diseases: Bull's-eye or missing the mark?

Arthritis and Rheumatism

Volumn 46, Issue 1, 2002, Pages 13-20

  Mengshol, John A ^a   Mix, Kimberlee S ^a   Brinckerhoff, Constance E ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX METALLOPROTEINASE INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; DRUG MECHANISM; DRUG USE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ARTHRITIS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MATRIX METALLOPROTEINASES;

EID: 0036159161     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200201)46:1<13::AID-ART497>3.0.CO;2-S     Document Type: Review

References (61)

1. New insights into plaque stabilisation by lipid lowering
2. Matrix metalloproteinases: Multifunctional contributors to tumor progression
3. Matrix metalloproteinases
4. Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion
5. Differential expression pattern of membrane-type matrix metalloproteinases in rheumatoid arthritis
6. Expression of membrane type 1 matrix metalloproteinase in human articular cartilage
7. Expression of membrane-type 1 matrix metalloproteinase and activation of progelatinase A in human osteoarthritic cartilage
8. Analysis of intraarticular fibrinolytic pathways in patients with inflammatory and noninflammatory joint diseases
9. Using inhibitors of metalloproteinases to treat arthritis: Easier said than done?
10. Joint destruction in arthritis: Metalloproteinases in the spotlight
11. Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis
12. Gene expression of matrix metalloproteinases 1, 3, and 9 by chondrocytes in osteoarthritic human knee articular cartilage is zone and grade specific
13. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage
14. Osteoarthritic lesions: Involvement of three different collagenases
15. Regulating expression of the gene for matrix metalloproteinase-1 (collagenase): Mechanisms that control enzyme activity, transcription, and mRNA stability
16. Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: Associations with degenerative changes
17. Pathogenesis of osteoarthritis
18. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage
19. In situ zymographic localisation of type II collagen degrading activity in osteoarthritic human articular cartilage
20. Purification and cloning of aggrecanase-1: A member of the ADAMTS family of proteins
21. Aggrecanase versus matrix metalloproteinases in the catabolism of the interglobular domain of aggrecan in vitro
22. Susceptibility of stromelysin 1-deficient mice to collagen-induced arthritis and cartilage destruction
23. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes
24. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice
25. Matrix metalloproteinase-7-dependent release of tumor necrosis factor-α in a model of herniated disc resorption
26. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover
27. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I
28. Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice
29. Inhibition of cartilage and bone destruction in adjuvant arthritis in the rat by a matrix metalloproteinase inhibitor
30. Ro 32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the STR/ORT mouse model of osteoarthritis
31. Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo
32. Interaction of α2-macroglobulin with matrix metalloproteinases and its use for identification of their active forms
33. Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions
34. Matrix metalloproteinases: Biologic activity and clinical implications
35. Ongoing trials with matrix metalloproteinase inhibitors
36. Thirty-six years in the clinic without an MMP inhibitor: What hath collagenase wrought?
37. Matrix metalloproteinase inhibition: From the Jurassic to the third millennium
38. Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors
39. Signal transduction and transcription factors in rheumatic disease
40. Studies on the contribution of c-fos/AP-1 to arthritic joint destruction
41. Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor κB: Differential regulation of collagenase 1 and collagenase 3
42. Actions of IL-1 are selectively controlled by p38 mitogen-activated protein kinase: Regulation of prostaglandin H synthase-2, metalloproteinases, and IL-6 at different levels
43. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function
44. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis
45. Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models
46. C-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis
47. Integration of the NF-κB and mitogen-activated protein kinase/AP-1 pathways at the collagenase-1 promoter: Divergence of IL-1 and TNF-dependent signal transduction in rabbit primary synovial fibroblasts
48. NF-κB: A key role in inflammatory diseases
49. Distinct roles for the NF-κB1 (p50) and c-Rel transcription factors in inflammatory arthritis
50. Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor κB decoy oligodeoxynucleotides as a gene therapy
51. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: An absolute requirement for transcription factor NF-κB
52. Nuclear factor κB/p50 activates an element in the distal matrix metalloproteinase 1 promoter in interleukin-1β-stimulated synovial fibroblasts
53. Defining therapeutic targets by using adenovirus: Blocking NF-κB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators
54. A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity
55. A synthetic triterpenoid selectively inhibits the induction of matrix metalloproteinases 1 and 13 by inflammatory cytokines
56. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
57. Infliximab and methotrexate in the treatment of rheumatoid arthritis
58. Cellular mechanisms for human procollagenase-3 (MMP-13) activation: Evidence that MT1-MMP (MMP-14) and gelatinase A (MMP-2) are able to generate active enzyme
59. Biochemical characterization of human collagenase-3
60. Cell migration through extracellular matrix: Membrane-type metalloproteinases make the way
61. Matrix metalloproteinases 19 and 20 cleave aggrecan and cartilage oligomeric matrix protein (COMP)